Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Acquired Immunodeficiency Syndrome HELP
Based on 7,985 articles published since 2008
||||

These are the 7985 published articles about Acquired Immunodeficiency Syndrome that originated from Worldwide during 2008-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. 2018

Bamford, A / Turkova, A / Lyall, H / Foster, C / Klein, N / Bastiaans, D / Burger, D / Bernadi, S / Butler, K / Chiappini, E / Clayden, P / Della Negra, M / Giacomet, V / Giaquinto, C / Gibb, D / Galli, L / Hainaut, M / Koros, M / Marques, L / Nastouli, E / Niehues, T / Noguera-Julian, A / Rojo, P / Rudin, C / Scherpbier, H J / Tudor-Williams, G / Welch, S B / Anonymous71257. ·Department of Paediatric Infectious Diseases and Immunology, Great Ormond Street Hospital NHS Trust, London, UK. · Medical Research Council Clinical Trials Unit, London, UK. · Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK. · Institute of Child Health, University College London, London, UK. · Radboud University Medical Center, Nijmegan, The Netherlands. · University Department of Immunology and Infectious Disease, Bambino Gesù Children's Hospital, Rome, Italy. · Our Lady's Children's Hospital Crumlin & University College Dublin, Dublin, Ireland. · Meyer University Hospital, Florence University, Florence, Italy. · HIV i-Base, London, UK. · Emilio Ribas Institute of Infectious Diseases, Sao Paulo, Brazil. · Paediatric Infectious Disease Unit, Luigi Sacco Hospital, University of Milan, Milan, Italy. · Department of Paediatrics, University of Padua, Padua, Italy. · Department of Health Sciences, Pediatric Unit, University of Florence, Florence, Italy. · Department of Pediatrics, CHU Saint-Pierre, Free University of Brussels, Brussels, Belgium. · Portsmouth Hospitals NHS Trust, Portsmouth, UK. · Paediatric Infectious Diseases and Immunodeficiencies Unit, Pediatric Department, Porto Central Hospital, Porto, Portugal. · Department of Clinical Microbiology and Virology, University College London Hospitals, London, UK. · Centre for Pediatric and Adolescent Medicine, HELIOS Hospital Krefeld, Krefeld, Germany. · Infectious Diseases Unit, Pediatrics Department, Sant Joan de Déu Hospital, University of Barcelona, Barcelona, Spain. · 12th of October Hospital, Madrid, Spain. · University Children's Hospital, Basel, Switzerland. · Department of Paediatric Immunology and Infectious Diseases, Emma Children's Hospital Academic Medical Centre, Amsterdam, The Netherlands. · Imperial College, London, UK. · Heartlands Hospital, Birmingham, UK. ·HIV Med · Pubmed #25649230.

ABSTRACT: The 2015 Paediatric European Network for Treatment of AIDS (PENTA) guidelines provide practical recommendations on the management of HIV-1 infection in children in Europe and are an update to those published in 2009. Aims of treatment have progressed significantly over the last decade, moving far beyond limitation of short-term morbidity and mortality to optimizing health status for adult life and minimizing the impact of chronic HIV infection on immune system development and health in general. Additionally, there is a greater need for increased awareness and minimization of long-term drug toxicity. The main updates to the previous guidelines include: an increase in the number of indications for antiretroviral therapy (ART) at all ages (higher CD4 thresholds for consideration of ART initiation and additional clinical indications), revised guidance on first- and second-line ART recommendations, including more recently available drug classes, expanded guidance on management of coinfections (including tuberculosis, hepatitis B and hepatitis C) and additional emphasis on the needs of adolescents as they approach transition to adult services. There is a new section on the current ART 'pipeline' of drug development, a comprehensive summary table of currently recommended ART with dosing recommendations. Differences between PENTA and current US and World Health Organization guidelines are highlighted and explained.

2 Guideline Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016). 2016

Anonymous901059. · ·Enferm Infecc Microbiol Clin · Pubmed #27068257.

ABSTRACT: In this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The objective of ART is to achieve an undetectable plasma viral load (PVL). Initial ART should comprise 3 drugs, namely, 2 nucleoside reverse transcriptase inhibitors (NRTI), and 1 drug from another family. Four of the recommended regimens, all of which have an integrase strand transfer inhibitor (INSTI) as the third drug, are considered a preferred regimen; a further 6 regimens, which are based on an INSTI, a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor boosted with cobicistat or ritonavir (PI/COBI, PI/r), are considered alternatives. The reasons and criteria for switching ART are presented both for patients with an undetectable PVL and for patients who experience virological failure, in which case the rescue regimen should include 3 (or at least 2) drugs that are fully active against HIV. The specific criteria for ART in special situations (acute infection, HIV-2 infection, pregnancy) and comorbid conditions (tuberculosis and other opportunistic infections, kidney disease, liver disease, and cancer) are updated.

3 Guideline Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). 2014

Anonymous2100799 / Berenguer, Juan / Polo, Rosa / Lozano, Fernando / López Aldeguer, José / Antela, Antonio / Arribas, José Ramón / Asensi, Víctor / Blanco, José Ramón / Clotet, Bonaventura / Domingo, Pere / Galindo, María José / Gatell, José María / González-García, Juan / Iribarren, José Antonio / Locutura, Jaime / López, Juan Carlos / Mallolas, Josep / Martínez, Esteban / Miralles, Celia / Miró, José M / Moreno, Santiago / Palacios, Rosario / Pérez Elías, María Jesús / Pineda, Juan Antonio / Podzamczer, Daniel / Portilla, Joaquín / Pulido, Federico / Ribera, Esteban / Riera, Melchor / Rubio, Rafael / Santos, Jesús / Sanz, Jesús / Tuset, Montserrat / Vidal, Francesc / Rivero, Antonio. · ·Enferm Infecc Microbiol Clin · Pubmed #24986715.

ABSTRACT: In this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The strength and grade of the recommendation varies with clinical circumstances, number of CD4 cells, comorbid conditions and prevention of transmission of HIV. The objective of ART is to achieve an undetectable plasma viral load. Initial ART should always comprise a combination of 3 drugs, including 2 nucleoside reverse transcriptase inhibitors and a third drug from a different family (non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor). This update presents the causes and criteria for switching ART in patients with undetectable plasma viral load and in cases of virological failure. An update is also provided for the specific criteria for ART in special situations (acute infection, HIV-2 infection, and pregnancy) and with comorbid conditions (tuberculosis or other opportunistic infections, kidney disease, liver disease, and cancer).

4 Guideline [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)]. 2014

Anonymous2130798 / Anonymous2140798. · ·Enferm Infecc Microbiol Clin · Pubmed #24953253.

ABSTRACT: OBJECTIVE: This consensus document is an update of combined antiretroviral therapy (cART) guidelines for HIV-1 infected adult patients. METHODS: To formulate these recommendations a panel composed of members of the Grupo de Estudio de Sida and the Plan Nacional sobre el Sida reviewed the efficacy and safety advances in clinical trials, cohort and pharmacokinetic studies published in medical journals (PubMed and Embase) or presented in medical scientific meetings. Recommendations strength and the evidence in which they are supported are based on modified criteria of the Infectious Diseases Society of America. RESULTS: In this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The strength and grade of the recommendation varies with the clinical circumstances: CDC stage B or C disease (A-I), asymptomatic patients (depending on the CD4+ T-lymphocyte count: <350cells/μL, A-I; 350-500 cells/μL, A-II, and >500 cells/μL, B-III), comorbid conditions (HIV nephropathy, chronic hepatitis caused by HBV or HCV, age >55years, high cardiovascular risk, neurocognitive disorders, and cancer, A-II), and prevention of transmission of HIV (mother-to-child or heterosexual, A-I; men who have sex with men, A-III). The objective of ART is to achieve an undetectable plasma viral load. Initial ART should always comprise a combination of 3 drugs, including 2 nucleoside reverse transcriptase inhibitors and a third drug from a different family (non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor). Some of the possible initial regimens have been considered alternatives. This update presents the causes and criteria for switching ART in patients with undetectable plasma viral load and in cases of virological failure where rescue ART should comprise 2 or 3 drugs that are fully active against the virus. An update is also provided for the specific criteria for ART in special situations (acute infection, HIV-2 infection, and pregnancy) and with comorbid conditions (tuberculosis or other opportunistic infections, kidney disease, liver disease, and cancer). CONCLUSIONS: These new guidelines updates previous recommendations related to cART (when to begin and what drugs should be used), how to monitor and what to do in case of viral failure or drug adverse reactions. cART specific criteria in comorbid patients and special situations are equally updated.

5 Guideline [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)]. 2013

Anonymous3460773. · ·Enferm Infecc Microbiol Clin · Pubmed #24161378.

ABSTRACT: OBJECTIVE: This consensus document is an update of combined antiretroviral therapy (cART) guidelines for HIV-1 infected adult patients. METHODS: To formulate these recommendations a panel composed of members of the GeSIDA/National AIDS Plan Secretariat (Grupo de Estudio de Sida and the Secretaría del Plan Nacional sobre el Sida) reviewed the efficacy and safety advances in clinical trials, cohort and pharmacokinetic studies published in medical journals (PubMed and Embase) or presented in medical scientific meetings. The strength of the recommendations and the evidence which support them are based on a modification of the criteria of Infectious Diseases Society of America. RESULTS: cART is recommended in patients with symptoms of HIV infection, in pregnant women, in serodiscordant couples with high risk of transmission, in hepatitisB co-infection requiring treatment, and in HIV nephropathy. cART is recommended in asymptomatic patients if CD4 is <500cells/μl. If CD4 are >500cells/μl cART should be considered in the case of chronic hepatitisC, cirrhosis, high cardiovascular risk, plasma viral load >100.000 copies/ml, proportion of CD4 cells <14%, neurocognitive deficits, and in people aged >55years. The objective of cART is to achieve an undetectable viral load. The first cART should include 2 reverse transcriptase inhibitors (RTI) nucleoside analogs and a third drug (a non-analog RTI, a ritonavir boosted protease inhibitor, or an integrase inhibitor). The panel has consensually selected some drug combinations, for the first cART and specific criteria for cART in acute HIV infection, in tuberculosis and other HIV related opportunistic infections, for the women and in pregnancy, in hepatitisB or C co-infection, in HIV-2 infection, and in post-exposure prophylaxis. CONCLUSIONS: These new guidelines update previous recommendations related to first cART (when to begin and what drugs should be used), how to monitor, and what to do in case of viral failure or adverse drug reactions. cART specific criteria in comorbid patients and special situations are similarly updated.

6 Guideline Executive summary of the Consensus Document of GeSIDA and Spanish Secretariat for the National Plan on AIDS on combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013). 2013

Anonymous2710773. · ·Enferm Infecc Microbiol Clin · Pubmed #24156952.

ABSTRACT: In the present update of the guidelines, a starting combination antiretroviral treatment (cART) is recommended in symptomatic patients, in pregnant women, in serodiscordant couples with a high risk of transmission, in patients co-infected with hepatitis B virus requiring treatment, and in patients with HIV-related nephropathy. Guidelines on cART are included in the event of a concurrent diagnosis of HIV infection with an AIDS-defining event. In asymptomatic naïve patients, cART is recommended if the CD4(+) lymphocyte count is <500cells/μL; if the CD4(+) lymphocyte count is >500cells/μL, cART can be delayed, although it may be considered in patients with liver cirrhosis, chronic infection due to hepatitis C virus, high cardiovascular risk, plasma viral load (PVL) >10(5)copies/mL, CD4(+) lymphocyte percentage <14%, cognitive impairment, and age >55 years. cART in naïve patients requires a combination of 3 drugs, and its aim is to achieve undetectable PVL. Treatment adherence plays a key role in sustaining a favorable response. cART can, and should be, changed if virological failure occurs, in order to return to undetectable PVL. Approaches to cART in acute HIV infection, in women, in pregnancy, in tuberculosis, and post-exposure prophylaxis are also examined.

7 Guideline Executive summary. Consensus statement of the National AIDS Plan Secretariat, Spanish Society of Emergency Medicine and AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology on Emergency and HIV Infection. 2013

Anonymous2110756. ·rpolor@msssi.es ·Enferm Infecc Microbiol Clin · Pubmed #23601917.

ABSTRACT: Emergency Services (ES) are the cornerstone of our health system and therefore it cannot remain indifferent to the HIV advances that have drastically changed the landscape of the disease, so, emergency specialist updating is not only necessary, it is also essential. The purpose of this paper is to support non-HIV specialist professionals in treating patients with urgent diseases resulting from HIV infection or related to it.

8 Guideline [The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)]. 2013

Rivero, Antonio / Pulido, Federico / Caylá, Joan / Iribarren, José A / Miró, José M / Moreno, Santiago / Pérez-Camacho, Inés / Anonymous2920754 / Anonymous2930754. ·Panel de Expertos del Grupo de estudio de Sida (GESIDA-SEIMC) y de la Secretaría del Plan Nacional sobre el Sida (SPNS) · Unidad de Enfermedades Infecciosas, Hospital Universitario 1050 Reina Sofía-IMIBIC, Córdoba, España. Electronic address: ariveror@gmail.com. ·Enferm Infecc Microbiol Clin · Pubmed #23541879.

ABSTRACT: This consensus document was prepared by an expert panel of the Grupo de Estudio de Sida (GESIDA [Spanish AIDS Study Group]) and the Plan Nacional sobre el Sida (PNS [Spanish National AIDS Plan]). The document updates current guidelines on the treatment of tuberculosis (TB) in HIV-infected individuals contained in the guidelines on the treatment of opportunistic infections published by GESIDA and PNS in 2008. The document aims to facilitate the management and treatment of HIV-infected patients with TB in Spain, and includes specific sections and recommendations on the treatment of drug-sensitive TB, multidrug-resistant TB, and extensively drug-resistant TB, in this population. The consensus guidelines also make recommendations on the treatment of HIV-infected patients with TB in special situations, such as chronic liver disease, pregnancy, kidney failure, and transplantation. Recommendations are made on the timing and initial regimens of antiretroviral therapy in patients with TB, and on immune reconstitution syndrome in HIV-infected patients with TB who are receiving antiretroviral therapy. The document does not cover the diagnosis of TB, diagnosis/treatment of latent TB, or treatment of TB in children. The quality of the evidence was evaluated and the recommendations graded using the approach of the Grading of Recommendations Assessment, Development and Evaluation Working Group.

9 Guideline Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA). 2013

Fidler, S / Anderson, J / Azad, Y / Delpech, V / Evans, C / Fisher, M / Gazzard, B / Gill, N / Lazarus, L / Lowbury, R / Orton, K / Osoro, B / Radcliffe, K / Smith, B / Churchill, D / Rogstad, K / Cairns, G. ·Imperial College London, London, UK. s.fidler@imperial.ac.uk ·HIV Med · Pubmed #23489936.

ABSTRACT: -- No abstract --

10 Guideline The 2010 South African guidelines for the management of HIV and AIDS: a review. 2011

Rossouw, Theresa / Richter, Karin / Martin, Des / Avenant, Theuns / Spencer, David. ·Department of Family Medicine, University of Pretoria. theresa.rossouw@up.ac.za ·S Afr Med J · Pubmed #21786723.

ABSTRACT: -- No abstract --

11 Guideline [Acquired immunodeficiency syndrome]. 2010

Anonymous1980678. · ·Rev Chilena Infectol · Pubmed #21046725.

ABSTRACT: -- No abstract --

12 Guideline [Acquired immunodeficiency syndrome]. 2010

Anonymous590669. · ·Rev Chilena Infectol · Pubmed #20737127.

ABSTRACT: -- No abstract --

13 Guideline [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. 2010

Anonymous2780663 / Anonymous2790663. · ·Enferm Infecc Microbiol Clin · Pubmed #20554079.

ABSTRACT: OBJECTIVE: This consensus document is an update of antiretroviral therapy recommendations for adult patients with human immunodeficiency virus infection. METHODS: To formulate these recommendations a panel made up of members of the Grupo de Estudio de Sida (Gesida, AIDS Study Group) and the Plan Nacional sobre el Sida (PNS, Spanish AIDS Plan) reviewed the advances in the current understanding of the pathophysiology of human immunodeficiency virus (HIV) infection, the efficacy and safety of clinical trials, and cohort and pharmacokinetic studies published in biomedical journals or presented at scientific meetings. Three levels of evidence were defined according to the data source: randomized studies (level A), cohort or case-control studies (level B), and expert opinion (level C). The decision to recommend, consider or not to recommend ART was established in each situation. RESULTS: Currently, the treatment of choice for chronic HIV infection is the combination of three drugs of two different classes, including 2 nucleosides or nucleotide analogs (NRTI) plus 1 non-nucleoside (NNRTI) or 1 boosted protease inhibitor (PI/r), but other combinations are possible. Initiation of ART is recommended in patients with symptomatic HIV infection. In asymptomatic patients, initiation of ART is recommended on the basis of CD4 lymphocyte counts, plasma viral load and patient co-morbidities, as follows: 1) therapy should be started in patients with CD4 counts below 350 cells/microl; 2) When CD4 counts are between 350 and 500 cells/microl, therapy should be started in case of cirrhosis, chronic hepatitis C, high cardiovascular risk, HIV nephropathy, HIV viral load above 100,000 copies/ml, proportion of CD4 cells under 14%, and in people aged over 55; 3) Therapy should be deferred when CD4 are above 500 cells/microl, but could be considered if any of previous considerations concurs. Treatment should be initiated in case of hepatitis B requiring treatment and should be considered for reduce sexual transmission. The objective of ART is to achieve an undetectable viral load. Adherence to therapy plays an essential role in maintaining antiviral response. Therapeutic options are limited after ART failures but undetectable viral loads maybe possible with the new drugs even in highly drug experienced patients. Genotype studies are useful in these situations. Drug toxicity of ART therapy is losing importance as benefits exceed adverse effects. Criteria for antiretroviral treatment in acute infection, pregnancy and post-exposure prophylaxis are mentioned as well as the management of HIV co-infection with hepatitis B or C. CONCLUSIONS: CD4 cells counts, viral load and patient co-morbidities are the most important reference factors to consider when initiating ART in asymptomatic patients. The large number of available drugs, the increased sensitivity of tests to monitor viral load, and the ability to determine viral resistance is leading to a more individualized therapy approach in order to achieve undetectable viral load under any circumstances.

14 Editorial HIV-No time for complacency. 2018

Abdool Karim, Quarraisha / Abdool Karim, Salim S. ·Quarraisha Abdool Karim (top) and Salim S. Abdool Karim (bottom) are professors at the Mailman School of Public Health at Columbia University, New York, NY, USA, and are the associate scientific director and director, respectively, of the Centre for the AIDS Programme of Research in South Africa (CAPRISA) at the University of KwaZulu-Natal, Durban, South Africa. quarraisha.abdoolkarim@caprisa.org salim.abdoolkarim@caprisa.org. ·Science · Pubmed #29903942.

ABSTRACT: -- No abstract --

15 Editorial Presenting national HIV/AIDS and sexually transmitted disease research in Brazil. 2018

Benzaken, Adele Schwartz / Oliveira, Maria Cristina Pimenta / Pereira, Gerson Fernando Mendes / Giozza, Silvana Pereira / Souza, Flavia Moreno Alves de / Cunha, Alessandro Ricardo Caruso da / Girade, Renato. ·Department of Surveillance, Prevention and Control of STIs, HIV/AIDS and Viral Hepatitis, Ministry of Health, Brasília, Brazil. ·Medicine (Baltimore) · Pubmed #29794602.

ABSTRACT: -- No abstract --

16 Editorial The Global Fund under Peter Sands. 2018

The Lancet, ?. · ·Lancet · Pubmed #29536843.

ABSTRACT: -- No abstract --

17 Editorial The End of Acquired Immunodeficiency Syndrome (AIDS) in Singapore - Are We There Yet? 2017

Tan, Glorijoy Se / Tambyah, Paul A. ·Institute of Infectious Diseases and Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore. ·Ann Acad Med Singapore · Pubmed #29355281.

ABSTRACT: -- No abstract --

18 Editorial Options for affordable pre-exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe. 2017

Coleman, Rosalind / Prins, Maria. ·PrEP consultant, The Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland. · Public Health Service of Amsterdam and Academic Medical Center, Amsterdam, The Netherlands. ·Euro Surveill · Pubmed #29067904.

ABSTRACT: -- No abstract --

19 Editorial Innovation at the Intersection of Alcohol and HIV Research. 2017

van Heerden, Alastair / Tomlinson, Mark / Skeen, Sarah / Parry, Charles / Bryant, Kendal / Rotheram-Borus, Mary Jane. ·Human Sciences Research Council, 22 Mbuvu Dr, Sweetwater, 3201, Pietermaritzburg, South Africa. avanheerden@hsrc.ac.za. · MRC/Wits Developmental Pathways for Health Research Unit, University of the Witwatersrand, Johannesburg, South Africa. avanheerden@hsrc.ac.za. · Department of Psychology, Stellenbosch University, Stellenbosch, South Africa. · Alcohol, Tobacco and Other Drug Research Unit, Medical Research Council, Cape Town, South Africa. · Department of Psychiatry, Stellenbosch University, Tygerberg, South Africa. · National Institute on Alcohol Abuse and Alcoholism, Rockville, MD, USA. · Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California at Los Angeles, Los Angeles, CA, USA. ·AIDS Behav · Pubmed #29043466.

ABSTRACT: Working in an interdisciplinary manner at the crossroads of alcohol and HIV research is a challenge. This paper presents six novel approaches that could be applied to activities at the intersection of alcohol and HIV. These approaches are (i) address the fact that the availability of new technology is unevenly distributed around the world, (ii) use technology to move beyond both paper and digital surveys, (iii) introduce a focus on advocacy and partnerships with large technology companies, (iv) harness technological innovation to utilise digital counselling, (v) explore the use of virtual reality in both research and delivering interventions, and (vi) consider alternative funding models to those currently in existence to improve efficiencies and innovations. Aiming to understand the interplay of alcohol and HIV will require creativity. The six approaches outlines in this paper provide possible directions from which new approaches may emerge.

20 Editorial Divergent paths to the end of AIDS. 2017

The Lancet Hiv, ?. · ·Lancet HIV · Pubmed #28865608.

ABSTRACT: -- No abstract --

21 Editorial HIV Prevention: The Promise of Pre-Exposure Prophylaxis in Singapore. 2017

Wong, Chen Seong. ·Infectious Diseases Department, Tan Tock Seng Hospital, Singapore. ·Ann Acad Med Singapore · Pubmed #28821889.

ABSTRACT: -- No abstract --

22 Editorial Are we anywhere near there yet? The state of harm reduction in North America in 2017. 2017

Drucker, Ernest / Crofts, Nick. ·College of Global Public Health, New York University, New York, USA. ed102@nyu.edu. · Nossal Institute, School of Population and Global Health, University of Melbourne, Melbourne, Australia. ·Harm Reduct J · Pubmed #28814308.

ABSTRACT: -- No abstract --

23 Editorial Initiatives to fill the gaps in Africa's AIDS response. 2017

The Lancet Hiv, ?. · ·Lancet HIV · Pubmed #28750741.

ABSTRACT: -- No abstract --

24 Editorial The global HIV/AIDS epidemic-progress and challenges. 2017

The Lancet, ?. · ·Lancet · Pubmed #28745587.

ABSTRACT: -- No abstract --

25 Editorial Farewell Mark. 2017

Hankins, Catherine. ·Deputy Director, Amsterdam Institute for Global Health and Development; Professor of Population and Public Health, Faculty of Medicine, McGill University, Montreal, QC. catherine.hankins@mcgill.ca. ·Can J Public Health · Pubmed #28621644.

ABSTRACT: -- No abstract --

Next